![]() Krishnamurthy H.K., Jayaraman V., Krishna K., Rajasekaran K.E., Wang T., Bei K., Rajasekaran J.J., Yaskin I., Rai A.J., Choung R.S., et al. Canadian Society of Clinical Chemists (CSCC) Interim Consensus Guidance for Testing and Reporting of SARS-CoV-2 Serology. ![]() The assessment of antibody responses to SARS-CoV-2 using DBS may be feasible using a quantitative anti-S assay, although false negatives may rarely occur in those with very low antibody levels.ĬOVID-19 SARS-CoV-2 antibody dried blood spot serology.īailey D., Konforte D., Barakauskas V.E., Yip P.M., Kulasingam V., Abou E.H.M., Beach L.A., Blasutig I.M., Catomeris P., Dooley K.C., et al. High concordance between plasma and fingerpick DBS was observed in PCR-confirmed COVID-19 patients tested 90 days or more after the diagnosis (45/46 matched 1/46 mismatched plasma vs. Quantitative results from DBS samples were highly correlated with values from plasma ( r 2 = 0.98), allowing for extrapolation using DBS results to accurately estimate plasma antibody levels. Antibody levels were reduced relative to plasma following elution from DBS. We investigated the characteristics of Roche's Anti-SARS-CoV-2 (S) assay, a quantitative commercial assay for antibodies against the spike glycoprotein. DBS collection could be used to facilitate widespread testing for SARS-CoV-2 antibodies to document past infection, vaccination, and potentially immunity. ![]() Dried blood spots (DBS) are commonly used for serologic testing for viruses and provide an alternative collection method when phlebotomy and/or conventional laboratory testing are not readily available.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |